Medical Xpress May 27, 2024
A randomized, placebo-controlled clinical trial led by a collaboration between Duke-NUS Medical School, National Heart Center Singapore (NHCS) and Klinikum Nürnberg, Germany, has revealed surprising new insights into how SGLT2 inhibitor drugs, originally developed for diabetes, benefit patients with heart failure.
Contrary to common assumptions, these drugs may improve cardiac outcomes and heart health without acting as diuretics.
Heart failure is a condition where the heart cannot pump enough blood to meet the body’s demands, often leading to fluid build-up in tissues and congestion of the blood circulation. This congestion strains the heart and causes symptoms like breathlessness and swelling.
Reducing congestion is key to managing heart failure, as it reduces the workload of the heart and thereby eases pumping.
...Today's Sponsors
Today's Sponsor